https://wikem.org/w/index.php?title=Naltrexone&feed=atom&action=history
Naltrexone - Revision history
2024-03-29T06:24:21Z
Revision history for this page on the wiki
MediaWiki 1.38.2
https://wikem.org/w/index.php?title=Naltrexone&diff=335910&oldid=prev
Jonrako: /* Mechanism of Action */
2022-01-17T05:26:28Z
<p><span dir="auto"><span class="autocomment">Mechanism of Action</span></span></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 05:26, 17 January 2022</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l52">Line 52:</td>
<td colspan="2" class="diff-lineno">Line 52:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Mechanism of Action==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Mechanism of Action==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>* <del style="font-weight: bold; text-decoration: none;">Opioid </del>competitive receptor antagonist</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>* <ins style="font-weight: bold; text-decoration: none;">Potent nonselective opioid </ins>competitive receptor antagonist</div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*Reduces the rewarding effects of alcohol consumption by inhibiting the activity of endogenous opioids in the mesolimbic system. <ref>Anderson, E., Chamberlin, M., Zuluaga, M., Ullal, M., &amp; Hawk, K. (2021). Annals of emergency medicine. Annals of Emergency Medicine, 78(6), 752–758. </ref></ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Comments==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Comments==</div></td></tr>
</table>
Jonrako
https://wikem.org/w/index.php?title=Naltrexone&diff=226831&oldid=prev
ClaireLewis: Created page with "==Administration== *Type: Opioid antagonist *Dosage Forms: *Routes of Administration: PO, IM *Common Trade Names: ReVia, Vivitrol, Depade ==Adult Dosing== *Opioid dependence..."
2019-09-01T23:11:18Z
<p>Created page with "==Administration== *Type: Opioid antagonist *Dosage Forms: *Routes of Administration: PO, IM *Common Trade Names: ReVia, Vivitrol, Depade ==Adult Dosing== *Opioid dependence..."</p>
<p><b>New page</b></p><div>==Administration==<br />
*Type: Opioid antagonist<br />
*Dosage Forms:<br />
*Routes of Administration: PO, IM<br />
*Common Trade Names: ReVia, Vivitrol, Depade<br />
<br />
==Adult Dosing==<br />
*Opioid dependence (prevention of relapse after opioid-free x 7-10d), ETOH dependence: 25-50mg PO daily OR 380mg IM q4w<br />
<br />
==Pediatric Dosing==<br />
''Safety/efficacy not established''<br />
<br />
==Special Populations==<br />
===[[Drug pregnancy categories|Pregnancy Rating]]===<br />
*Category C<br />
<br />
===Lactation risk===<br />
*Minimally excreted in breastmilk<br />
<br />
===Renal Dosing===<br />
*Use caution<br />
<br />
===Hepatic Dosing===<br />
*Use caution<br />
<br />
==Contraindications==<br />
*Allergy to class/drug<br />
*Patients who are on opioid analgesics/partial agonists, are opioid-dependant, or in acute opioid withdrawal<br />
<br />
==Adverse Reactions==<br />
===Serious===<br />
*Depression, suicide, and suicidality<br />
*Vulnerability to opioid overdose: Patients should be alerted that they may be more sensitive to opioids, even at lower doses, after discontinuance of naltrexone<br />
*Hepatotoxicity<br />
*Severe injection-site reactions (e.g. necrosis, cellulitis, hematoma)<br />
<br />
<br />
===Common===<br />
*Injection site reaction<br />
*Nausea/vomiting, diarrhea, decreased appetite, dry mouth<br />
*LFT abnormalities,<br />
*Elevated CPK<br />
*Headache, dizziness, anxiety, insomnia, somnolence<br />
*URI, pharyngitis<br />
*Arthralgia, muscle cramps, back pain<br />
*Rash<br />
<br />
==Pharmacology==<br />
*Half-life: PO- 4-13h;IM- 5-10 days<br />
*Metabolism: Hepatic<br />
*Excretion: Urinary<br />
<br />
==Mechanism of Action==<br />
* Opioid competitive receptor antagonist<br />
<br />
==Comments==<br />
<br />
<br />
==See Also==<br />
*[[Opioids]]<br />
<br />
==References==<br />
<references/><br />
<br />
[[Category:Pharmacology]]</div>
ClaireLewis